Histone deacetylase inhibitors and kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2019.05.007

Abstract

Abstract:

Histone deacetylation is one of the important ways of epigenetic modification of histones. Histone deacetylases (HDACs), as key proteins in regulating genes, has long been confirmed to be closely related to the occurrence and development of tumors, neurodegenerative diseases, and kidney diseases, promoting the development and clinical application of HDAC inhibitors (HDACi). This article reviewed the role of HDACs in the development and progression of kidney diseases, as well as the application prospect of HDACi in the treatment of kidney diseases.

Key words: Epigenetics, Histone, Histone deacetylase inhibitor, Kidney disease

Xiaoyan Du, Yuying Feng, Liang Ma, Ping Fu. Histone deacetylase inhibitors and kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(05): 226-229.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2019.05.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2019/V08/I05/226

References 30

[1]	Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in immune-oncology [J]. Nat Rev Cancer, 2019, 19(3): 151-161.
[2]	Emmett MJ, Lazar MA. Integrative regulation of physiology by histone deacetylase 3 [J]. Nat Rev Mol Cell Biol, 2019, 20(2): 102-115.
[3]	Liang T, Fang H. Structure, functions and selective inhibitors of HDAC6 [J]. Curr Top Med Chem, 2018, 18(28): 2429-2447.
[4]	Batchu SN, Brijmohan AS, Advani A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease [J]. Clin Sci, 2016, 130(12): 987-1003.
[5]	Kosciuk T, Wang M, Hong JY, et al. Updates on the epigenetic roles of sirtuins [J]. Curr Opin Chem Biol, 2019, 51: 18-29.
[6]	Sun L, Marin de Evsikova C, Bian K, et al. Programming and regulation of metabolic homeostasis by HDAC11 [J]. EBioMedicine, 2018, 33: 157-168.
[7]	Zupkovitz G, Lagger S, Martin D, et al. Histone deacetylase 1 expression is inversely correlated with age in the short-lived fish Nothobranchius furzeri [J]. Histochem Cell Biol, 2018, 150(3): 255-269.
[8]	Bacon T, Seiler C, Wolny M, et al. Histone deacetylase 3 indirectly modulates tubulin acetylation [J]. Biochem J, 2015, 472(3): 367-377.
[9]	Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy [J]. Cell, 2002, 110(4): 479-488.
[10]	Chen S, El-Dahr SS. Histone deacetylases in kidney development: implications for disease and therapy [J]. Pediatr Nephrol, 2013, 28(5): 689-698.
[11]	Qin HT, Li HQ, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives [J]. Expert Opin Ther Pat, 2017, 27(5): 621-636.
[12]	Shi Y, Xu L, Tang J, et al. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury [J]. Am J Physiol Renal Physiol, 2017, 312(3): F502-F515.
[13]	Tang J, Shi Y, Liu N, et al. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury [J]. Clin Sci, 2018, 132(3): 339-359.
[14]	Feng Y, Huang R, Guo F, et al. Selective histone deacetylase 6 inhibitor 23BB alleviated rhabdomyolysis-induced acute kidney injury by regulating endoplasmic reticulum stress and apoptosis [J]. Front Pharmacol, 2018, 9: 274.
[15]	Marumo T, Hishikawa K, Yoshikawa M, et al. Epigenetic regulation of BMP7 in the regenerative response to ischemia [J]. J Am Soc Nephrol, 2008, 19(7): 1311-1320.
[16]	Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury [J]. Nat Med, 2003, 9(7): 964-968.
[17]	Imai N, Hishikawa K, Marumo T, et al. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury [J]. Stem Cells, 2007, 25(10): 2469-2475.
[18]	de Boer IH. A new chapter for diabetic kidney disease [J]. N Engl J Med, 2017, 377(9): 885-887.
[19]	Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney [J]. Nat Rev Nephrol, 2017, 13(10): 629-646.
[20]	Advani A, Huang Q, Thai K, et al. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism [J]. Am J Pathol, 2011, 178(5): 2205-2214.
[21]	Gilbert RE, Huang Q, Thai K, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor [J]. Kidney Int, 2011, 79(12): 1312-1321.
[22]	Noh H, Oh EY, Seo JY, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury [J]. Am J Physiol Renal Physiol, 2009, 297(3): F729-F739.
[23]	Tan AY, Zhang T, Michaeel A, et al. Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease [J]. J Am Soc Nephrol, 2018, 29(8): 2139-2156.
[24]	Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models [J]. Proc Natl Acad Sci USA, 2009, 106(51): 21819-21824.
[25]	Zhou X, Fan LX, Sweeney WE, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease [J]. J Clin Invest, 2013, 123(7): 3084-3098.
[26]	Li Y, Zhang X, Polakiewicz RD, et al. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization [J]. J Biol Chem, 2008, 283(19): 12686-12690.
[27]	Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy [J]. Am J Physiol Renal Physiol, 2009, 297(4): F996-F1005.
[28]	Choi SY, Piao ZH, Jin L, et al. Piceatannol attenuates renal fibrosis induced by unilateral ureteral obstruction via downregulation of histone deacetylase 4/5 or p38-MAPK signaling [J]. PLoS One, 2016, 11(11): e0167340.
[29]	Marumo T, Hishikawa K, Yoshikawa M, et al. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury [J]. Am J Physiol Renal Physiol, 2010, 298(1): F133-F141.
[30]	Van Beneden K, Geers C, Pauwels M, et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis [J]. Toxicol Applied Pharmacol, 2013, 271(2): 276-284.

Please choose a citation manager

Content to export